Research

Energy balance

23% of participants reported any adverse event while using GLP-1RAs, with 7% discontinuing treatment.

While GLP-1RAs are generally well-tolerated, practitioners should monitor for adverse events.

StrongQualifiesmedium confidence
23% (95% CI, 10%-36%) of participants reported any adverse event but only 7% discontinued treatment.
Caroline K. Kramer et al. · The Journal of Clinical Endocrinology & Metabolism · 2024

Why this rating

Based on a systematic review and meta-analysis of 17 studies.

Source

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment

Caroline K. Kramer et al. · The Journal of Clinical Endocrinology & Metabolism · 2024

DOI 10.1210/clinem/dgae176

Meta-analysisCited 23×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →